GenScript Biotech Earns EcoVadis Bronze Medal for the Second Consecutive Year, Ranking Above 83% of Companies

PISCATAWAY, N.J., March 26, 2025 /PRNewswire/ -- GenScript Biotech Corporation (GenScript), a global leader in life sciences research, manufacturing technologies and production services, has been awarded the EcoVadis Bronze Medal for the second year in a row, recognizing its strong sustainability performance. This achievement reflects GenScript's continued progress in environmental stewardship, labor and human rights, ethics, and sustainable procurement, reaffirming its commitment to global best practices.

This year, GenScript ranked ahead of 83% of all companies assessed by EcoVadis and placed in the top 10% in the manufacture of basic pharmaceutical products and pharmaceutical preparations industry—a significant improvement from its previous assessment. This milestone further underscores GenScript's dedication to sustainability and its role as a trusted partner for the global life science and healthcare ecosystem.

"We are proud to receive the EcoVadis Bronze Medal for the second consecutive year with significant improvement in our performance. This recognition underscores our unwavering commitment to sustainability and responsible business practices," said Sherry Shao, Rotating CEO of GenScript Biotech Corporation. "At GenScript, we believe that sustainability is not just a goal, but a fundamental part of our mission to make people and nature healthier through biotechnology. By optimizing operations and collaborating with our value chain, we have taken steps forward in reducing environmental impact, promoting ethical practices, and fostering social responsibility over the past year. We will build on this momentum and work with global business partners to create long-term value."

EcoVadis, a globally recognized sustainability rating platform, evaluates companies based on international standards, including the Global Reporting Initiative (GRI), the United Nations Global Compact (UNGC), and ISO 26000. Covering over 220 industries and more than 180 countries and regions, its assessments measure corporate sustainability performance across environmental impact, labor and human rights, business ethics, and sustainable procurement.

Beyond EcoVadis, GenScript's sustainability efforts have received broader global recognition. In 2023, GenScript joined the United Nations Global Compact (UNGC), committing to the Ten Principles on human rights, labor, environment, and anti-corruption. In 2024, GenScript and its subsidiary, ProBio, strengthened their sustainability commitments by becoming supplier partners of the Pharmaceutical Supply Chain Initiative (PSCI), contributing to a greener and more ethical pharmaceutical supply chain.

In capital markets, GenScript's ESG initiatives have also been highly recognized, with its MSCI ESG rating improving from BBB to A, reflecting its strong environmental, social, and governance (ESG) performance. Additionally, in February 2025, GenScript's carbon reduction targets were officially validated by the Science Based Targets initiative (SBTi), marking a major milestone in the company's global decarbonization journey.

Looking ahead, GenScript remains committed to embedding sustainability into its DNA, continuing to innovate and collaborate to advance the long-term health of both society and the planet.

About GenScript Biotech Corporation

Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in healthcare and consumer goods by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology and its role as a trusted global leader, GenScript has a team of over 5,500 employees and has served more than 200,000 customers across over 100 countries and regions.

Learn more here: https://www.genscript.com 

SOURCE GenScript Biotech Corporation